Documents | Ranibizumab for treating diabetic macular oedema | Guidance | NICE

Documents

A list of downloadable documents created during development.

Background information

TA274 Macular oedema (diabetic) - ranibizumab: review decision - April 2015 information
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - GE decision paper - March 2015 10 April 2015 67.61 KB
TA274 Macular oedema (diabetic) - ranibizumab: review proposal - February 2015 information
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - GE proposal paper February 2015 23 February 2015 499.6 KB
TA274 Macular oedema (diabetic) - ranibizumab: appendix A - matrix of stakeholders 23 February 2015 40.72 KB
TA274 Macular oedema (diabetic) - ranibizumab: press release information
NICE Single Technology Appraisal process guide 06 December 2013 285.78 KB

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): equality impact assessment - guidance development

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): equality impact assessment - guidance development 02 July 2013 18.24 KB

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination information
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final appraisal determination guidance 04 January 2013 277.51 KB
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) 04 January 2013 138.28 KB
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): consultee and commentator comments on the ACD
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis 04 January 2013 189.3 KB
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Diabetes UK 04 January 2013 66.94 KB
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RNIB 04 January 2013 27.98 KB
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RCP and ABCD 04 January 2013 13.76 KB
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): CSAS 04 January 2013 107.58 KB
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Department of Health 04 January 2013 8.33 KB
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): comments on the ACD received from the public through the NICE website 04 January 2013 83.23 KB

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): appraisal consultation document information
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): evaluation report
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): pre-meeting briefing 05 October 2012 86.01 KB
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Evidence Review Group report for NICE rapid review 05 October 2012 319.01 KB
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis 05 October 2012 299.13 KB

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final scope

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): final scope 05 October 2012 28.15 KB